References
Gander M, Leyvraz S, Decosterd L, Bonfanti M, Marzolini C, Shen F et al (1999) Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol 10:831–838
Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25(22):3357–3361
Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR (1994) Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1, 3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 54:3793–3799
Chang SM, Prados MD, Yung WKA et al (2004) Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American brain tumor consortium trial. Cancer 100:1712–1716
Silvani A, Lamperti E, Gaviani P, Eoli M, Fiumani A, Salmaggi A, Falcone C, Filippini G, Botturi A, Boiardi A (2008) Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol 87(2):143–151
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gaviani, P., Salmaggi, A. & Silvani, A. Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients. J Neurooncol 104, 617–618 (2011). https://doi.org/10.1007/s11060-010-0515-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-010-0515-z